Chifaou Mohamed-Djalim
Institut Gustave Roussy(FR)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Hepatocellular Carcinoma Treatment and Prognosis, Pancreatic and Hepatic Oncology Research, Immunotherapy and Immune Responses
Most-Cited Works
- → Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers(2022)27 cited
- → Immune checkpoints are predominantly co-expressed by clonally expanded CD4+FoxP3+ intratumoral T-cells in primary human cancers(2023)9 cited
- → Cytokines Released by Human Tumors are Independent from Cancer Histotype(2025)
- → 1286P Senescent immune phenotype (SIP) status predicts resistance to immune checkpoint blockers (ICB) among CMV+ advanced non-small cell lung cancer (aNSCLC) patients(2021)
- → Abstract 6042: Baseline serum level of IgG targeting annexin A2 is predictive of response to immunotherapy in patients with advanced NSCLC(2025)
- → 183 Fresh tumor analysis enables rapid characterization of prognostic subgroups and identifies novel therapeutic targets for early-stage hepatocellular carcinoma(2025)